Brief: Elicio Therapeutics Announces Clinical Supply Agreement With Regeneron To Evaluate ELI-002 In Combination With Libtayo In Kras-Driven Tumors
Brief: Angion Announces Phase 1B Trial Of Ang-3070 In Patients With Idiopathic Pulmonary Fibrosis
Angion Biomedica Corp expected to post a loss of 43 cents a share - Earnings Preview
Angion Biomedica Corp reports results for the quarter ended in December - Earnings Summary
Brief: Angion Provides Corporate Update And Reports Full Year 2021 Financial Results
Brief: Elicio Therapeutics - Presents Updated Preclinical Data On Eli-005
Angion Biomedica Corp expected to post a loss of 62 cents a share - Earnings Preview
Brief: Angion Biomedica Corp - First Patient Enrolled In Phase 2 Trial Of ANG-3070 In Primary Proteinuric Kidney Diseases
U.S. STOCKS ON THE MOVE-Oracle, Lucid Group, Broadcom, Chewy, Everbridge
Angion set to hit record low as kidney injury therapy fails to meet main goal
U.S. STOCKS ON THE MOVE-Costco, Lululemon, Peloton, Nuance Communications
Brief: Vifor Pharma And Angion Report Topline Results From Phase-II Guard Trial Of Ang-3777
Brief: Angion And Vifor Pharma Report Topline Results From Phase 2 Guard Trial Of ANG-3777 In Cardiac Surgery-Associated Acute Kidney Injury
Brief: Angion Reports Q3 Loss Per Share Of 53 Cents
Brief: Angion And Vifor Pharma Report Topline Results From Phase 3 Trial Of Ang-3777 In Kidney Transplant Patients At Risk For Delayed Graft Function
Brief: Elicio Therapeutics Announces First Patient Dosed In The Eli-002 (Amplify-201) Study In Kras-Driven Cancers
Brief: Elicio Presents Preclinical Data On AMP TCR-T Combination Therapy In Solid Tumors At CAR-TCR Annual Summit 2021
Brief: Angion Biomedica Corp Says On August 27, Co Received Written Notice From Sinovant Sciences Hk Limited - SEC Filing
Angion Biomedica Corp reports results for the quarter ended in June - Earnings Summary